50 results  1 of 3 

1 Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus
Jae Hyun Bae, Hyung Jin Choi, Kang Ik Kevin Cho, Lee Kyung Kim, Jun Soo Kwon, Young Min Cho
Diabetes Metab J.2020;44(2):248-259.   Published online 2019 November 4     DOI: http://dx.doi.org/10.4093/dmj.2019.0018
      
2 Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
Inkuk Lee, Eun Seok Kang
J Korean Diabetes.2019;20(3):149-156.   Published online 2019 September 30     DOI: http://dx.doi.org/10.4093/jkd.2019.20.3.149
      
3 A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinol Metab.2019;34(3):247-262.   Published online 2019 September 26     DOI: http://dx.doi.org/10.3803/EnM.2019.34.3.247
   
4 Saxenda® Frenzy: Opinions of an Endocrine and Metabolism Specialist
Sungrae Kim
J Korean Diabetes.2019;20(2):63-66.   Published online 2019 June 30     DOI: http://dx.doi.org/10.4093/jkd.2019.20.2.63
      
5 Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals
Chang Ho Ahn, Jae Hyun Bae, Young Min Cho
Diabetes Metab J.2019;43(6):879-892.   Published online 2019 June 25     DOI: http://dx.doi.org/10.4093/dmj.2018.0202
      
6 Anti-diabetic effects of blue honeyberry on high-fed-diet-induced type II diabetic mouse
Anshul Sharma, Joo Wan Kim, Sae-Kwang Ku, Jae-Suk Choi, Hae-Jeung Lee
Nutr Res Pract.2019;13(5):367-376.   Published online 2019 June 12     DOI: http://dx.doi.org/10.4162/nrp.2019.13.5.367
      
7 Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus
Soyeon Yoo, Eun-Jin Yang, Gwanpyo Koh
Diabetes Metab J.2019;43(4):495-503.   Published online 2019 February 20     DOI: http://dx.doi.org/10.4093/dmj.2018.0105
      
8 Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis
Hyeonhui Kim, Sungsoon Fang
Lab Anim Res.2018;34(4):140-146.   Published online 2018 December 31     DOI: http://dx.doi.org/10.5625/lar.2018.34.4.140
      
9 Effect of Nutrient Preload and Food Order on Glucose, Insulin, and Gut Hormones
Jae Hyun Bae, Young Min Cho
J Korean Diabetes.2018;19(4):193-199.   Published online 2018 December 28     DOI: http://dx.doi.org/10.4093/jkd.2018.19.4.193
      
10 Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
Diabetes Metab J.2019;43(4):410-421.   Published online 2018 December 27     DOI: http://dx.doi.org/10.4093/dmj.2018.0070
      
11 Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet
Vincenza Spallone
Diabetes Metab J.2019;43(1):3-30.   Published online 2018 November 2     DOI: http://dx.doi.org/10.4093/dmj.2018.0259
      
12 Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018
Jeong Hyun Park
J Korean Diabetes.2018;19(2):71-75.   Published online 2018 June 30     DOI: http://dx.doi.org/10.4093/jkd.2018.19.2.71
      
13 Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
In-Kyung Jeong
J Lipid Atheroscler.2018;7(1):32-41.   Published online 2018 June 27     DOI: http://dx.doi.org/10.12997/jla.2018.7.1.32
      
14 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim
J Korean Diabetes.2018;19(1):35-40.   Published online 2018 March 27     DOI: http://dx.doi.org/10.4093/jkd.2018.19.1.35
      
15 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi,
Diabetes Metab J.2017;41(6):423-429.   Published online 2017 December 19     DOI: http://dx.doi.org/10.4093/dmj.2017.41.6.423
      
16 New anti-diabetic agents
Doo-Man Kim
J Korean Med Assoc.2017;60(12):992-997.   Published online 2017 December 14     DOI: http://dx.doi.org/10.5124/jkma.2017.60.12.992
      
17 Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
Yu Mi Kang, Chang Hee Jung
Endocrinol Metab.2017;32(3):316-325.   Published online 2017 September 18     DOI: http://dx.doi.org/10.3803/EnM.2017.32.3.316
   
18 New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
Won-Young Lee
Endocrinol Metab.2017;32(1):1-5.   Published online 2017 February 6     DOI: http://dx.doi.org/10.3803/EnM.2017.32.1.1
   
19 Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes Mellitus
Sang Ah Lee, Gwanpyo Koh, Suk Ju Cho, So-Yeon Yoo, Sang Ouk Chin
Endocrinol Metab.2016;31(3):439-445.   Published online 2016 September 26     DOI: http://dx.doi.org/10.3803/EnM.2016.31.3.439
      
20 An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Suk Chon, Jean-François Gautier
Diabetes Metab J.2016;40(2):99-114.   Published online 2016 April 25     DOI: http://dx.doi.org/10.4093/dmj.2016.40.2.99
      

 1 of 3